TrianglePUBLICATIONS · 24976003
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Pediatr Blood Cancer
- Publication date
- 2014 Oct
- First author
- Horton TM
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Horton TM
- type
- Author
- name
- Perentesis JP
- type
- Author
- name
- Gamis AS
- type
- Author
- name
- Alonzo TA
- type
- Author
- name
- Gerbing RB
- type
- Author
- name
- Ballard J
- type
- Author
- name
- Adlard K
- type
- Author
- name
- Howard DS
- type
- Author
- name
- Smith FO
- type
- Author
- name
- Jenkins G
- type
- Author
- name
- Kelder A
- type
- Author
- name
- Schuurhuis GJ
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Horton TM
- type
- Author
- name
- Perentesis JP
- type
- Author
- name
- Gamis AS
- type
- Author
- name
- Alonzo TA
- type
- Author
- name
- Gerbing RB
- type
- Author
- name
- Ballard J
- type
- Author
- name
- Adlard K
- type
- Author
- name
- Howard DS
- type
- Author
- name
- Smith FO
- type
- Author
- name
- Jenkins G
- type
- Author
- name
- Kelder A
- type
- Author
- name
- Schuurhuis GJ
- type
- Author
- bibliography ids
- nci-bib-ecf185606a2865ef185c2dd6
- book metadata
- content sha256
- 9fa8f40c914a599f1086cc52205bac1dfbfe2388580cf3ae320e407add082b5b
- document type
- citation
- dois
- 10.1002/pbc.25117
- electronic publication date
- display
- 2014 Jun 29
- precision
- day
- year
- 2014
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:24976003
- immutable id
- pubmed:24976003@9fa8f40c914a599f1086cc52205bac1dfbfe2388580cf3ae320e407add082b5b
- journal
- abbreviation
- Pediatr Blood Cancer
- issn electronic
- 1545-5017
- issn print
- 1545-5009
- issue
- 10
- name
- Pediatric blood & cancer
- nlm unique id
- 101186624
- pages
- 1754-60
- volume
- 61
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 24976003
- provenance
- batch id
- 69903be8ceab8801c81a
- provider
- NCBI PubMed ESummary
- record sha256
- d953d459919e0bd4656e3df6875abe1bc2fae7a534962e259a3e40c35ae7e502
- response sha256
- 1e367491c3c459a93f45b3db99ca1f9293ed2287c48bdf758bb088ffcd7c96eb
- retrieved at
- 2026-09-09T23:47:05.208886+00:00
- publication date
- display
- 2014 Oct
- precision
- month
- year
- 2014
- publication types
- Clinical Trial, Phase II
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
Preserved source evidence · Not medical advice